{"schema_version":"secwatch.filing_event.v1","accession":"0000926617-24-000009","form_type":"8-K","ticker":"AWHL","cik":"0000926617","company_name":"Aspira Women's Health Inc.","filed_at":"2024-03-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.322432+00:00","generated_at":"2026-06-04T06:52:41.103595+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Aspira Women's Health 2023 rev $9.2M (+15% YoY); cash burn halved to $15.9M","bullets":["Q4 product revenue $2.1M flat YoY; OvaSuite volume ~5,659 tests.","Full year 2023 OvaSuite volume 23,990 units (+12% YoY); AUP $382.","Cash used in operations $15.9M for 2023, down 49% from $31.1M in 2022.","Gross margin improved to 57.5% from 52.8% on lower lab/shipping costs.","Raised $5.5M in registered direct offering post year-end; cash $2.9M at Dec 31."],"urls":{"canonical":"https://secwatch.observer/filing/0000926617-24-000009","json":"https://secwatch.observer/filing/0000926617-24-000009.json","markdown":"https://secwatch.observer/filing/0000926617-24-000009.md","text":"https://secwatch.observer/filing/0000926617-24-000009.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/926617/000092661724000009/0000926617-24-000009-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/926617/000092661724000009/awh-20240328x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T06:52:41.103595+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f93edf9443757127ba292f842ca35b7cef5a2370","claim":"Aspira Women's Health Inc. reported the fourth quarter and year ended December 31, 2023 results: revenue Product revenue was $2.1 million for the three months ended December 31, 2023.","evidence_excerpt":"Aspira Women’s Health Inc. (the “Company”) issued a press release reporting financial results for the three and twelve months ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/926617/000092661724000009/0000926617-24-000009-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and year ended December 31, 2023"},{"label":"Revenue","value":"Product revenue was $2.1 million for the three months ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}